Please ensure Javascript is enabled for purposes of website accessibility

Moderna Seals Deal to Supply Israel with Coronavirus Vaccine

By Eric Volkman – Updated Jun 16, 2020 at 10:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

By acting now, the Israeli Health Ministry says it's avoiding long delays in getting the country's citizens a COVID-19 vaccine later.

Many of the companies working to develop SARS-CoV-2 coronavirus vaccines aren't waiting around for clinical trials to be complete or government regulators to give their approval. They're ramping up manufacturing of their candidates even before it's clear whether or not they're effective at preventing COVID-19.

Taking a similar approach, at least one foreign government just signed a deal to buy a supply of one of those candidates before it becomes a licensed (and in-demand) pharmaceutical product: Israel's Health Ministry on Tuesday inked a deal with Moderna (MRNA -3.34%) for a quantity of its hopeful COVID-19 vaccine, dubbed mRNA-1273.

Contingent on the vaccine working, the U.S.-based biotech will deliver a significant quantity of mRNA-1273 once it becomes available, according to reports in Hebrew-language media. The particulars of the arrangement, such as deliverables and price, have not yet been made public, and Moderna hasn't made an official statement on the deal.

Although Moderna is far from the only biotech or pharmaceutical company developing a SARS-CoV-2 vaccine, it is relatively advanced in its progress and mRNA-1273 has shown excellent promise in phase 2 trials so far.


Image source: Getty Images.

Recently, the company said it will begin a large-scale phase 3 study of its candidate next month, in collaboration with the National Institutes of Health. If that trial proves successful and the company wins regulatory approval, it says it can start to mass-produce the vaccine by the end of this year and deliver 1 billion doses by mid-2021.

The mRNA-1273 vaccine works by blocking the production of a protein that allows the novel coronavirus to latch onto cells. That keeps it from reproducing and spreading through the body.

Due to the urgency of containing the pandemic, research into COVID-19 vaccines has been accelerated significantly compared to the usual pace of pharmaceutical development. Other notable biotech and pharmaceutical companies developing such solutions include AstraZeneca, Pfizer, and Novavax. An unnamed Health Ministry source was also quoted in the newspaper Israel Hayom as saying that the country plans to strike additional deals with other vaccine companies.

Moderna shares did well Monday, partly on the anticipation that ran ahead this deal. They closed nearly 7.4% higher, convincingly beating the gains of the broader stock market on the day. But shares were down in early trading Tuesday, off by more than 4% as of 10:40 a.m. EDT.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$118.07 (-3.34%) $-4.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.